ENJUVIA (estrogens, conjugated synthetic b) by Aspen Surgical is clinical pharmacology endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Approved for the: treatment of moderate to severe vasomotor symptoms associated with menopause. First approved in 2004.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
ENJUVIA is an oral tablet containing conjugated synthetic estrogens B, approved for treatment of moderate to severe vasomotor symptoms associated with menopause. The drug works by binding to estrogen receptors in estrogen-responsive tissues and modulating pituitary secretion of gonadotropins to reduce elevated hormone levels in postmenopausal women. It is a small-molecule hormone replacement therapy with slow gastrointestinal absorption over several hours.
With LOE approaching and no active portfolio expansion, ENJUVIA represents a consolidation/legacy product role with stable but declining team engagement opportunities.
CLINICAL PHARMACOLOGY Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal…
Worked on ENJUVIA at Aspen Surgical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy
Aspen Surgical is hiring 3 roles related to this product
Working on ENJUVIA offers limited career growth due to LOE approaching; roles are concentrated in key account management and customer service rather than innovation-focused commercial or medical functions. This product is best suited for professionals seeking stability in account stewardship or those managing transition into post-LOE portfolio strategies.
4 open roles linked to this drug